Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 37 Carcinoma, Non-Small-Cell Lung 24 Melanoma 19 Squamous Cell Carcinoma of Head and Neck 18 Colorectal Neoplasms 16 Urinary Bladder Neoplasms 11 Breast Neoplasms 11 Lung Neoplasms 10 Liver Neoplasms 10 Biliary Tract Neoplasms 10 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Carcinoma, Renal Cell 9 Neoplasms 8 Cholangiocarcinoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Adenocarcinoma Of Esophagus 6 Stomach Neoplasms 5 Neoplasm Metastasis 5 Mesothelioma, Malignant 5 Fallopian Tube Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Mesothelioma 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3

Interventions

Drug Therapy 2 tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 atezolizumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-invasive Bladder Cancer × tremelimumab × Clear all

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡